Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

[Situation and Problems of Activities for Cancer Cooperative Treatment in Kumamoto].

Sakai K, Kishi H, Ohtake H, Hamaguchi H, Yoshida M, Gotoh K, Hida N, Uchiyama E, Nakagawa M, Miyamoto N, Ehara M, Adachi M, Ihara K, Uemura Y, Usuku K, Katabuchi H.

Gan To Kagaku Ryoho. 2019 Jul;46(7):1151-1157. Japanese.

PMID:
31296821
2.

Correction to: Long-term results of intersphincteric resection for low rectal cancer in Japan.

Yamada K, Saiki Y, Takano S, Iwamoto K, Tanaka M, Fukunaga M, Noguchi T, Nakamura Y, Hisano S, Fukami K, Kuwahara D, Tsuji Y, Takano M, Usuku K, Ikeda T, Sugihara K.

Surg Today. 2019 Apr;49(4):286-287. doi: 10.1007/s00595-019-1767-7.

PMID:
30734880
3.

Long-term results of intersphincteric resection for low rectal cancer in Japan.

Yamada K, Saiki Y, Takano S, Iwamoto K, Tanaka M, Fukunaga M, Noguchi T, Nakamura Y, Hisano S, Fukami K, Kuwahara D, Tsuji Y, Takano M, Usuku K, Ikeda T, Sugihara K.

Surg Today. 2019 Apr;49(4):275-285. doi: 10.1007/s00595-018-1754-4. Epub 2019 Jan 2. Review. Erratum in: Surg Today. 2019 Feb 8;:.

PMID:
30604217
4.

Matrix changes in articular cartilage in the knee of patients with rheumatoid arthritis after biological therapy: 1-year follow-up evaluation by T2 and T1ρ MRI quantification.

Hirose J, Nishioka H, Tsukano M, Matsubara S, Usuku K, Mizuta H.

Clin Radiol. 2018 Nov;73(11):984.e11-984.e18. doi: 10.1016/j.crad.2018.06.020. Epub 2018 Jul 30.

PMID:
30072032
5.

Web-Based Evaluation System to Measure Learning Effectiveness in Kampo Medicine.

Iizuka N, Usuku K, Nakae H, Segawa M, Wang Y, Ogashiwa K, Fujita Y, Ogihara H, Tazuma S, Hamamoto Y.

Evid Based Complement Alternat Med. 2016;2016:2043535. Epub 2016 Sep 22.

6.

Combined arteriosclerotic assessment of ankle-brachial index and maximum intima-media thickness via CCTA is useful for predicting coronary artery stenosis in patients with type 2 diabetes.

Yoshida A, Jinnouchi H, Sugiyama S, Hirose J, Segata T, Furuta K, Katahira K, Kajiwara K, Hieshima K, Jinnouchi T, Usuku K.

Diabetes Res Clin Pract. 2016 Jul;117:91-9. doi: 10.1016/j.diabres.2016.04.013. Epub 2016 Apr 27.

7.

Validity of E-PASS System for Postoperative Morbidity of Spinal Surgery.

Hirose J, Taniwaki T, Fujimoto T, Okada T, Nakamura T, Usuku K, Mizuta H.

J Spinal Disord Tech. 2015 Dec;28(10):E595-600. doi: 10.1097/BSD.0000000000000056.

PMID:
24270578
8.

Predictive value of E-PASS and POSSUM systems for postoperative risk assessment of spinal surgery.

Hirose J, Taniwaki T, Fujimoto T, Okada T, Nakamura T, Okamoto N, Usuku K, Mizuta H.

J Neurosurg Spine. 2014 Jan;20(1):75-82. doi: 10.3171/2013.9.SPINE12671. Epub 2013 Nov 8.

PMID:
24206035
9.

Articular cartilage lesions increase early cartilage degeneration in knees treated by anterior cruciate ligament reconstruction: T1ρ mapping evaluation and 1-year follow-up.

Hirose J, Nishioka H, Okamoto N, Oniki Y, Nakamura E, Yamashita Y, Usuku K, Mizuta H.

Am J Sports Med. 2013 Oct;41(10):2353-61. doi: 10.1177/0363546513496048. Epub 2013 Aug 7.

PMID:
23925576
10.

KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection.

Seich Al Basatena NK, Macnamara A, Vine AM, Thio CL, Astemborski J, Usuku K, Osame M, Kirk GD, Donfield SM, Goedert JJ, Bangham CR, Carrington M, Khakoo SI, Asquith B.

PLoS Pathog. 2011 Oct;7(10):e1002270. doi: 10.1371/journal.ppat.1002270. Epub 2011 Oct 13.

11.

Prediction of postoperative ambulatory status 1 year after hip fracture surgery.

Hirose J, Ide J, Yakushiji T, Abe Y, Nishida K, Maeda S, Anraku Y, Usuku K, Mizuta H.

Arch Phys Med Rehabil. 2010 Jan;91(1):67-72. doi: 10.1016/j.apmr.2009.09.018.

PMID:
20103398
12.

Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease.

Sabouri AH, Usuku K, Hayashi D, Izumo S, Ohara Y, Osame M, Saito M.

Blood. 2008 Sep 15;112(6):2411-20. doi: 10.1182/blood-2008-02-140335. Epub 2008 May 23.

13.

Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide.

Nose H, Kubota R, Seth NP, Goon PK, Tanaka Y, Izumo S, Usuku K, Ohara Y, Wucherpfennig KW, Bangham CR, Osame M, Saito M.

J Infect Dis. 2007 Dec 15;196(12):1761-72. doi: 10.1086/522966.

15.

Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy.

Arimura K, Nakagawa M, Izumo S, Usuku K, Itoyama Y, Kira J, Osame M.

J Neurovirol. 2007 Aug;13(4):364-72.

PMID:
17849320
16.

Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.

Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN.

Retrovirology. 2006 Sep 19;3:63.

18.
19.

Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease.

Nobuhara Y, Usuku K, Saito M, Izumo S, Arimura K, Bangham CR, Osame M.

Immunogenetics. 2006 Jan;57(12):944-52. Epub 2006 Jan 10.

PMID:
16402214
20.
21.

ApaI polymorphism of vitamin D receptor gene is associated with susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis in HTLV-1 infected individuals.

Saito M, Eiraku N, Usuku K, Nobuhara Y, Matsumoto W, Kodama D, Sabouri AH, Izumo S, Arimura K, Osame M.

J Neurol Sci. 2005 May 15;232(1-2):29-35.

PMID:
15850579
22.

Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals.

Sabouri AH, Saito M, Usuku K, Bajestan SN, Mahmoudi M, Forughipour M, Sabouri Z, Abbaspour Z, Goharjoo ME, Khayami E, Hasani A, Izumo S, Arimura K, Farid R, Osame M.

J Gen Virol. 2005 Mar;86(Pt 3):773-81.

PMID:
15722539
23.

Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriers.

Mori S, Mizoguchi A, Kawabata M, Fukunaga H, Usuku K, Maruyama I, Osame M.

Thorax. 2005 Feb;60(2):138-43.

24.

Human T cell lymphotropic virus type I (HTLV-I) p12I is dispensable for HTLV-I transmission and maintenance of infection in vivo.

Furukawa Y, Usuku K, Izumo S, Osame M.

AIDS Res Hum Retroviruses. 2004 Oct;20(10):1092-9.

PMID:
15585100
25.

Chronic progressive cervical myelopathy with HTLV-I infection: Variant form of HAM/TSP?

Umehara F, Nagatomo S, Yoshishige K, Saito M, Furukawa Y, Usuku K, Osame M.

Neurology. 2004 Oct 12;63(7):1276-80.

PMID:
15477551
27.

Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, Izumo S, Arimura K, Marshall SE, Usuku K, Bangham CR, Osame M.

J Infect Dis. 2004 Oct 1;190(7):1279-85. Epub 2004 Aug 31.

PMID:
15346339
28.
29.

Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis.

Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N, Kubota R, Takenouchi N, Nagai M, Furukawa Y, Usuku K, Izumo S, Osame M.

J Infect Dis. 2004 Jan 1;189(1):29-40. Epub 2003 Dec 31.

PMID:
14702150
30.
31.

[Physiopathology and treatment of HAM].

Osame M, Usuku K, Umehara F, Saito M, Furukawa Y, Kubota R, Nagai M, Higuchi I, Nakagawa M, Arimura K, Izumo S.

Nihon Naika Gakkai Zasshi. 2003 Sep 10;92(9):1673-82. Review. Japanese. No abstract available.

PMID:
14560601
32.
33.

Human T-cell lymphotropic virus type I (HTLV-I)-related clinical and laboratory findings for HTLV-I-infected blood donors.

Furukawa Y, Kubota R, Eiraku N, Nakagawa M, Usuku K, Izumo S, Osame M.

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):328-34.

PMID:
12626894
35.

Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers.

Saito M, Braud VM, Goon P, Hanon E, Taylor GP, Saito A, Eiraku N, Tanaka Y, Usuku K, Weber JN, Osame M, Bangham CR.

Blood. 2003 Jul 15;102(2):577-84. Epub 2003 Jan 30.

36.

Degenerate specificity of HTLV-1-specific CD8+ T cells during viral replication in patients with HTLV-1-associated myelopathy (HAM/TSP).

Kubota R, Furukawa Y, Izumo S, Usuku K, Osame M.

Blood. 2003 Apr 15;101(8):3074-81. Epub 2002 Dec 12.

37.

Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis.

Saito M, Higuchi I, Saito A, Izumo S, Usuku K, Bangham CR, Osame M.

J Infect Dis. 2002 Nov 1;186(9):1231-41. Epub 2002 Oct 7.

PMID:
12402192
38.

Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis.

Vine AM, Witkover AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE, Bunce M, Eiraku N, Izumo S, Usuku K, Osame M, Bangham CR.

J Infect Dis. 2002 Oct 1;186(7):932-9. Epub 2002 Sep 13.

PMID:
12232833
39.

HTLV-1-mediated immunopathological CNS disease.

Kitze B, Usuku K.

Curr Top Microbiol Immunol. 2002;265:197-211. Review.

PMID:
12014190
40.

HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, Kubota H, Izumo S, Akiba S, Osame M.

J Neurovirol. 2001 Jun;7(3):228-34.

PMID:
11517397
41.

Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1.

Wodarz D, Hall SE, Usuku K, Osame M, Ogg GS, McMichael AJ, Nowak MA, Bangham CR.

Proc Biol Sci. 2001 Jun 22;268(1473):1215-21.

42.

HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) with amyotrophic lateral sclerosis-like manifestations.

Matsuzaki T, Nakagawa M, Nagai M, Nobuhara Y, Usuku K, Higuchi I, Takahashi K, Moritoyo T, Arimura K, Izumo S, Akiba S, Osame M.

J Neurovirol. 2000 Dec;6(6):544-8.

PMID:
11175327
43.

In vivo selection of T-cell receptor junctional region sequences by HLA-A2 human T-cell lymphotropic virus type 1 Tax11-19 peptide complexes.

Saito M, Taylor GP, Saito A, Furukawa Y, Usuku K, Weber JN, Osame M, Bangham CR.

J Virol. 2001 Jan;75(2):1065-71.

44.

The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection.

Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osame M, Bangham CR.

J Immunol. 2000 Dec 15;165(12):7278-84.

45.
46.

Molecular pathologic analysis of the tonsil in HTLV-I-infected individuals.

Takenouchi N, Matsuoka E, Moritoyo T, Nagai M, Katsuta K, Hasui K, Ueno K, Eizuru Y, Usuku K, Osame M, Isashiki Y, Izumo S.

J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):200-7.

PMID:
10843536
47.

Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes.

Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR.

Blood. 2000 Feb 15;95(4):1386-92.

48.

CD44 splice variant involvement in the chronic inflammatory disease of the spinal cord: HAM/TSP.

Matsuoka E, Usuku K, Jonosono M, Takenouchi N, Izumo S, Osame M.

J Neuroimmunol. 2000 Jan 3;102(1):1-7.

PMID:
10626660
49.

Linkage analysis of candidate myelin genes in familial multiple sclerosis.

Seboun E, Oksenberg JR, Rombos A, Usuku K, Goodkin DE, Lincoln RR, Wong M, Pham-Dinh D, Boesplug-Tanguy O, Carsique R, Fitoussi R, Gartioux C, Reyes C, Ribierre F, Faure S, Fizames C, Gyapay G, Weissenbach J, Dautigny A, Rimmler JB, Garcia ME, Pericak-Vance MA, Haines JL, Hauser SL.

Neurogenetics. 1999 Sep;2(3):155-62.

PMID:
10541588
50.

Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients.

Saito M, Nakamura N, Nagai M, Shirakawa K, Sato H, Kawahigashi N, Furukawa Y, Usuku K, Nakagawa M, Izumo S, Osame M.

J Neuroimmunol. 1999 Aug 3;98(2):221-6.

PMID:
10430056

Supplemental Content

Support Center